RCP Pacifique : bilan après un an et 323 cancers rares et/ou complexes discutés

Abstract

Overseas France represents 18% of French territory and is home to 4% of its population for whom there is unequal treatment in the field of rare/complex cancer. To report our experience of intercontinental multidisciplinary videoconferencing between the French mainland and Pacific territories. Every other friday, three centers located in Papeete, Nouméa and Paris-Villejuif connected between 6:30 AM and 8:00 AM GMT to discuss cases of rare/complex cancers. Between November 2019 and December 2020, 323 presentations implicating 233 patients involved sarcoma (n=93), digestive pathology (n=60), neuroendocrine tumors (n=35), urology (n=24), gynecology (n=24), neurology (n=16), thyroid pathology (n=14), dermatology (n=14), senology (n=11), hematology (n=11), ENT pathology (n=10), pathology thoracic (n=10) and pediatrics (n=1). Of the 233 patients, 134 (57.5%) living in New Caledonia and 99 (42.5%) in French Polynesia, 117 (50.5%) had metastatic disease. 39 patients (16.7%) were transferred to French mainland (EVASAN), for surgery (n=25), vectorized radiotherapy (n=7), biopsy (n=5), chemotherapy (n=1) or inclusion in a clinical trial (n=1). 195 patients (83.7%) were treated at home, 15 (6.4%) are still awaiting a decision and 4 (1.7%) lost to follow-up. The use of videoconferencing to discuss rare/complex cancer cases was effective in guaranteeing French overseas population access to innovative therapies and clinical trials, limiting the need for intercontinental transfer to 16.7%.